ISONIAZID-BASED SCHIFF'S BASES IN BONE CANCER STUDIES USING MG-63 CELL LINES

Objective: Anticancer activities of Schiff bases S1 and S2 against MG-63 human osteosarcoma cells were performed and described using an in vitro evaluation employing cytotoxicity and apoptosis assay. Methods: MG-63 cells were used in an MTT assay to examine the effect of the compound on cell viabili...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of applied pharmaceutics 2022-07, p.168-174
Hauptverfasser: HEMALATHA, G. MUNI, THIRUNAVUKKARASU, KANDASAMY, KUMAR, C. RAMESH
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objective: Anticancer activities of Schiff bases S1 and S2 against MG-63 human osteosarcoma cells were performed and described using an in vitro evaluation employing cytotoxicity and apoptosis assay. Methods: MG-63 cells were used in an MTT assay to examine the effect of the compound on cell viability (S1 and S2). Cell morphologies and IC50 values were obtained. The acridine orange (AO)/ethidium bromide (EB) dual staining technique was used to determine the apoptosis process. Results: Our findings showed that synthesised S1 and S2 reduced MG-63 cell proliferation and induced apoptosis in a dose-dependent manner, implying that they could be used to treat bone cancer. Conclusion: Our findings showed that synthesised S1 and S2 reduced MG-63 cell proliferation and induced apoptosis in a dose-dependent manner, implying that they could be used to treat bone cancer.
ISSN:0975-7058
0975-7058
DOI:10.22159/ijap.2022.v14ti.48